Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 7/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17764302 | 0.95 | SUCNR1 (0.43) | SMN1; SMN2MAPTRAB9AP2RX3P2RX2 | |
| SCHEMBL17772668 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTRAB9AP2RX3P2RX2 | |
| SCHEMBL16409571 | 0.81 | CFD (0.48) | SMN1; SMN2MAPTRAB9ASUCNR1LMNA | |
| SCHEMBL16410450 | 0.81 | CFD (0.48) | SMN1; SMN2MAPTRAB9ASUCNR1LMNA | |
| SCHEMBL16396451 | 0.81 | HDAC1 (0.44) | MAPTSUCNR1HDAC1LMNA | |
| SCHEMBL16410368 | 0.80 | HDAC1 (0.44) | MAPTSUCNR1HDAC1 | |
| SCHEMBL16410364 | 0.80 | MAPT (0.37) | SMN1; SMN2MAPTRAB9AHDAC1LMNA | |
| SCHEMBL16397193 | 0.79 | SUCNR1 (0.47) | SUCNR1HDAC1 | |
| SCHEMBL16410451 | 0.79 | DDR2 (0.43) | SUCNR1HDAC1 | |
| SCHEMBL16410357 | 0.78 | HDAC1 (0.41) | MAPTSUCNR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | SMN1; SMN2 4625/4885MAPT 3865/4885RAB9A 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.